Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine the safety, tolerability, and effectiveness of 2 dose levels of LX6171 given over 28 days in patients with Age Associated Memory Impairment (AAMI).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lexicon Pharmaceuticals

Criteria

Inclusion Criteria:

• Males and females aged 60-80 years old.

• Complaints of memory loss in everyday life

• Non-smokers or very light smokers (no more than 10 cigarettes/day)

• Negative urine screen for drugs of abuse

• Ability to provide written informed consent

Exclusion Criteria:

• History or evidence of any disease, disorder or injury that could cause cognitive deterioration.

• Need for medications other than hormone replacement therapy, daily vitamins, or over-the-counter pain killers

• Clinically significant abnormality on electrocardiogram

• History of alcoholism or drug dependence

• Use of dietary supplements containing Huperzine A, gingko biloba, phosphatidylserine, or Docosahexaenoic acid (DHA)